MedTrace Logo

Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial

NCT00247312 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 319

Last updated 2015-11-17

No results posted yet for this study

Summary

The purpose of this study is to determine the most appropriate radiation implant dose for palladium-103 monotherapy. Radiation dose is related to potential cure. From previously published studies, it appears that the prescribed radiation dose can be reduced by 14-20% without any difference in potential cure (in this study, the dose is being decreased 10%). Although most patients tolerate brachytherapy well, complications to appear to be related to radiation exposure to normal structures (i.e. urethra, rectum and proximal penis). By reducing the prescribed dose, it is conceivable that fewer patients will experience side effects and complications.

Conditions

  • Prostatic Neoplasm

Interventions

RADIATION

Pd-103

Sponsors & Collaborators

  • Schiffler Cancer Center

    lead OTHER

Principal Investigators

  • Gregory S. Merrick, MD · Schiffler Cancer Center, Wheeling, WV

  • Kent E. Wallner, MD · Department of Veterans Affairs, Seattle, WA

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00247312 on ClinicalTrials.gov